Related Experiment Video
Updated: Jun 27, 2025

In vivo Evaluation of Mucociliary Clearance in Mice
Published on: December 18, 2020
Nontuberculous Mycobacteria, Mucociliary Clearance, and Bronchiectasis
Miriam Retuerto-Guerrero1, Ramiro López-Medrano2, Elizabeth de Freitas-González3
1Servicio de Reumatología, Complejo Asistencial Universitario de León, Gerencia Regional de Salud de Castilla y León (SACYL), Altos de Nava, s/n, 24071 León, Spain.
Ciliary dyskinesia, or impaired cilia function, is proposed as the primary driver of bronchiectasis, often involving nontuberculous mycobacteria (NTM). Therapeutic strategies targeting ciliary function and NTM biofilms may offer new treatment options.
Area of Science:
- Pulmonary Medicine
- Microbiology
- Genetics
Background:
- Bronchiectasis, characterized by airway dilation and chronic cough, is often linked to nontuberculous mycobacteria (NTM) pulmonary disease.
- The established Cole's vicious circle model suggests bronchiectasis develops from airway insults that impair mucociliary clearance, enabling microbial colonization.
- Ciliopathies, including primary ciliary dyskinesia and those in connective tissue diseases, are recognized risk factors for bronchiectasis.
Purpose of the Study:
- To propose a revised model of bronchiectasis pathogenesis.
- To highlight the central role of ciliary dyskinesia in bronchiectasis development.
- To identify nontuberculous mycobacteria (NTM) as key bacterial players in this process.
Main Methods:
- Literature review and synthesis of existing models.
- Analysis of the relationship between NTM, lung microbiome, and bronchiectasis.
- Conceptual framework development based on current evidence.
Main Results:
- Nontuberculous mycobacteria (NTM) are ubiquitous environmental bacteria, with specific species causing pulmonary disease.
- Increased incidence of NTM pulmonary disease parallels the rise in bronchiectasis cases.
- Ciliary dyskinesia is identified as the principal promoter of bronchiectasis, frequently involving NTM.
Conclusions:
- Ciliary dyskinesia is proposed as the main driver of bronchiectasis.
- Nontuberculous mycobacteria (NTM) are frequently implicated in NTM pulmonary disease and bronchiectasis.
- Restoring ciliary function and inhibiting NTM biofilm formation represent potential therapeutic avenues beyond antibiotics.
Related Concept Videos
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
The Bronchial Tree
The trachea, commonly known as the windpipe, is a tube that connects the larynx (voice box) to the bronchi. At a point called the carina, it bifurcates into two primary bronchi. The right primary bronchus is wider, shorter, and more vertical than the left primary...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...

